查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1763977

抗瘧藥物市場－全球產業規模、佔有率、趨勢、機會及預測（按藥物類型、瘧疾類型、地區和競爭情況分類，2020-2030 年）

Antimalarial Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Malaria Type, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球抗瘧藥物市場價值為 5.542 億美元，預計到 2030 年將達到 7.1104 億美元，複合年成長率為 4.44%。由於瘧疾在撒哈拉以南非洲和亞洲部分地區等地區依然普遍存在，對有效治療的需求依然強勁。青蒿素類聯合療法 (ACT) 憑藉其療效及其在標準治療方案中的既定作用繼續引領市場。為因應抗藥性瘧疾菌株的增加，研發投入不斷增加，進一步推動了市場發展。人們正在推行三重療法、長效注射劑和兒童改良製劑等創新，以提高療效和依從性。雖然不斷取得進展，但市場面臨著不斷變化的抗藥性模式帶來的持續挑戰，凸顯了持續開發新型治療方法的必要性。

市場概覽
預測期 2026-2030
2024年市場規模 5.542億美元
2030年市場規模 7.1104億美元
2025-2030 年複合年成長率 4.44%
成長最快的領域 奎寧
最大的市場 北美洲

關鍵市場促進因素

醫療保健產業的成長

主要市場挑戰

藥品供應不一致

主要市場趨勢

更注重草藥和植物療法

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：COVID-19 對全球抗瘧藥物市場的影響

第5章：全球抗瘧藥物市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依藥物類型（奎寧、氯奎、氯胍、阿莫地喹、甲氟喹、羥氯奎、乙胺嘧啶等）
    • 依瘧疾類型（惡性瘧原蟲、三日瘧原蟲、間日瘧原蟲、卵形瘧原蟲、諾氏瘧原蟲）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：北美抗瘧疾藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第7章：歐洲抗瘧疾藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太抗瘧藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章：南美抗瘧藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東和非洲抗瘧藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如有）
  • 最新動態

第13章：干擾：衝突、流行病與貿易壁壘

第 14 章：全球抗瘧藥物市場：SWOT 分析

第 15 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 16 章：競爭格局

  • Cipla Ltd
  • GlaxoSmithKline Plc
  • Ipca Laboratories Ltd.
  • Merck & Co., Inc
  • Novartis AG
  • Zydus Cadila
  • Sun Pharmaceutical Industries Ltd.
  • Strides Pharma Science Limited
  • Glenmark Pharmaceuticals Ltd.
  • Lincoln Pharmaceuticals Ltd.

第 17 章：策略建議

第18章調查會社について,免責事項

簡介目錄
Product Code: 5012

The Global Antimalarial Drugs Market was valued at USD 554.20 million in 2024 and is projected to reach USD 711.04 million by 2030, growing at a CAGR of 4.44%. With malaria remaining prevalent in regions like sub-Saharan Africa and parts of Asia, demand for effective treatments remains robust. Artemisinin-based combination therapies (ACTs) continue to lead the market due to their efficacy and established role in standard treatment protocols. The market is being further driven by increased investment in research and development aimed at addressing the rise in drug-resistant malaria strains. Innovations such as triple combination therapies, long-acting injectables, and improved formulations for children are being pursued to enhance effectiveness and adherence. While advancements continue, the market faces persistent challenges from evolving resistance patterns, highlighting the need for ongoing development of novel treatment approaches.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 554.20 Million
Market Size 2030USD 711.04 Million
CAGR 2025-20304.44%
Fastest Growing SegmentQuinine
Largest MarketNorth America

Key Market Drivers

Growth in Healthcare Industry

The sustained expansion of the global healthcare industry-projected to surpass USD 4 trillion annually-is significantly bolstering the antimalarial drugs market. Pharmaceuticals and biotechnology contribute nearly USD 850 billion, supported by diagnostics and medical technology. In malaria-endemic regions such as Africa, Asia, and Latin America, increased public and private investment in healthcare infrastructure has enhanced access to diagnostics and treatments. This improved accessibility enables timely intervention, allowing for broader administration of antimalarial drugs and supporting continuous market growth.

Key Market Challenges

Inconsistency in Drug Supply

Supply inconsistency remains a major hurdle in the global antimalarial drugs market, especially in regions where malaria is most prevalent. Despite advancements in drug development and distribution frameworks, many affected areas still experience irregular access to essential medications. This issue is most acute in remote or low-income regions with fragile healthcare infrastructure. Key contributing factors include limited manufacturing capacity, inefficient procurement systems, and logistical obstacles that lead to delayed or insufficient supply. Seasonal fluctuations in malaria cases-often linked to monsoon or rainy seasons-further strain these underprepared supply chains. Inadequate inventory control and fragmented distribution networks can result in stockouts at critical points of care, ultimately disrupting treatment and increasing health risks.

Key Market Trends

Increased Focus on Herbal and Plant-Based Therapies

There is a growing trend toward the development and adoption of herbal and plant-based therapies in the antimalarial drugs market. Plant-derived compounds such as quinine, quinidine, and artemisinin remain pivotal in the fight against malaria. This shift is largely influenced by rising interest in natural and traditional treatments, particularly in regions where indigenous medicine is widely practiced. Concerns regarding side effects of synthetic drugs and the emergence of resistant malaria strains have prompted researchers and pharmaceutical firms to explore botanical alternatives. Artemisinin-extracted from sweet wormwood-serves as a cornerstone of ACTs and exemplifies the clinical success of plant-based remedies. Ongoing exploration of other medicinal plants, including neem and cinchona bark, continues to expand the pipeline of potential antimalarial agents derived from natural sources.

Key Market Players

  • Cipla Ltd
  • GlaxoSmithKline Plc
  • Ipca Laboratories Ltd.
  • Merck & Co., Inc
  • Novartis AG
  • Zydus Cadila
  • Sun Pharmaceutical Industries Ltd.
  • Strides Pharma Science Limited
  • Glenmark Pharmaceuticals Ltd.
  • Lincoln Pharmaceuticals Ltd.

Report Scope

In this report, the Global Antimalarial Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antimalarial Drugs Market, By Drug Type:

  • Quinine
  • Chloroquine
  • Proguanil
  • Amodiaquine
  • Mefloquine
  • Hydroxychloroquine
  • Pyrimethamine
  • Others

Antimalarial Drugs Market, By Malaria Type:

  • Plasmodium Falciparum
  • Plasmodium Malariae
  • Plasmodium Vivax
  • Plasmodium Ovale
  • Plasmodium Knowlesi

Antimalarial Drugs Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antimalarial Drugs Market.

Available Customizations

Global Antimalarial Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Antimalarial Drugs Market

5. Global Antimalarial Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Quinine, Chloroquine, Proguanil, Amodiaquine, Mefloquine, Hydroxychloroquine, Pyrimethamine, Others)
    • 5.2.2. By Malaria Type (Plasmodium Falciparum, Plasmodium Malariae, Plasmodium Vivax, Plasmodium Ovale, Plasmodium Knowlesi)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Antimalarial Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Malaria Type
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Antimalarial Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Malaria Type
    • 6.3.2. Mexico Antimalarial Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Malaria Type
    • 6.3.3. Canada Antimalarial Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Malaria Type

7. Europe Antimalarial Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Malaria Type
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Antimalarial Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Malaria Type
    • 7.3.2. Germany Antimalarial Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Malaria Type
    • 7.3.3. United Kingdom Antimalarial Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Malaria Type
    • 7.3.4. Italy Antimalarial Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Malaria Type
    • 7.3.5. Spain Antimalarial Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Malaria Type

8. Asia Pacific Antimalarial Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Malaria Type
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Antimalarial Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Malaria Type
    • 8.3.2. India Antimalarial Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Malaria Type
    • 8.3.3. South Korea Antimalarial Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Malaria Type
    • 8.3.4. Japan Antimalarial Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Malaria Type
    • 8.3.5. Australia Antimalarial Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Malaria Type

9. South America Antimalarial Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Malaria Type
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Antimalarial Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Malaria Type
    • 9.3.2. Argentina Antimalarial Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Malaria Type
    • 9.3.3. Colombia Antimalarial Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Malaria Type

10. Middle East and Africa Antimalarial Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Malaria Type
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Antimalarial Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Malaria Type
    • 10.3.2. Saudi Arabia Antimalarial Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Malaria Type
    • 10.3.3. UAE Antimalarial Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Malaria Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Disruptions : Conflicts, Pandemics and Trade Barriers

14. Global Antimalarial Drugs Market: SWOT Analysis

15. Porters Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Products

16. Competitive Landscape

  • 16.1. Cipla Ltd
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (As Reported)
    • 16.1.5. Recent Developments
    • 16.1.6. Key Personnel Details
    • 16.1.7. SWOT Analysis
  • 16.2. GlaxoSmithKline Plc
  • 16.3. Ipca Laboratories Ltd.
  • 16.4. Merck & Co., Inc
  • 16.5. Novartis AG
  • 16.6. Zydus Cadila
  • 16.7. Sun Pharmaceutical Industries Ltd.
  • 16.8. Strides Pharma Science Limited
  • 16.9. Glenmark Pharmaceuticals Ltd.
  • 16.10. Lincoln Pharmaceuticals Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer